Elaine Posted October 10, 2004 Share Posted October 10, 2004 October 8, 2004 Genentech Inc. closed down 30 cents, or less than 1 percent, at $47.25 after spending much of the day up about 2 percent on an upgrade from Credit Suisse First Boston. CSFB said Avastin, the company's key colon cancer drug, is likely to post positive results from a late-stage study of its use for lung cancer. Mid-stage trials did not show any significant effect of Avastin in lung cancer patients, but CFSB said the phase III study is more targeted Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.